West Pharmaceutical Services Files 8-K

Ticker: WST · Form: 8-K · Filed: Feb 13, 2025 · CIK: 105770

Sentiment: neutral

Topics: financial-reporting, sec-filing, operations

Related Tickers: WST

TL;DR

WST filed an 8-K on Feb 13, 2025, covering financial results and operations.

AI Summary

On February 13, 2025, WEST PHARMACEUTICAL SERVICES, INC. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements and exhibits. No specific financial figures or operational details were provided in the excerpt.

Why It Matters

This 8-K filing indicates that West Pharmaceutical Services is providing updates on its financial condition and operations to the SEC, which is important for investors to monitor.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of financial information and does not appear to contain any immediate negative news.

Key Numbers

Key Players & Entities

FAQ

What specific financial results are being reported in this 8-K?

The provided excerpt states the filing concerns 'Results of Operations and Financial Condition' but does not detail specific financial figures.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported is February 13, 2025.

What is the company's principal executive office address?

The principal executive offices are located at 530 Herman O. West Drive, Exton, PA 19341-1147.

What is the Standard Industrial Classification (SIC) code for West Pharmaceutical Services, Inc.?

The SIC code is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.

What is the fiscal year end for West Pharmaceutical Services, Inc.?

The fiscal year end for the company is December 31 (1231).

Filing Stats: 658 words · 3 min read · ~2 pages · Grade level 9.4 · Accepted 2025-02-13 08:00:48

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On February 13, 2025, West Pharmaceutical Services, Inc. (the "Company") issued a press release announcing its fourth-quarter and full year 2024 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. The information set forth in "Item 2.02 Results of Operations and Financial Condition," including the exhibit referred to therein, is incorporated herein by reference. A copy of the Company's presentation materials used during the call will be available through the Investors link at the Company's website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.2 and incorporated herein by reference. The information in this report (including the exhibits attached hereto) is being furnished pursuant to Item 2.02 and Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibit No. Description 99.1 West Pharmaceutical Services, Inc. Press Release, dated February 13, 2025. 99.2 West Pharmaceutical Services, Inc. Presentation, dated February 13, 2025. 104 The cover page from the Company's Current Report on Form 8-K, dated February 13, 2025, formatted in Inline XBRL. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WEST PHARMACEUTICAL SERVICES, INC. /s/ Bernard J. Birkett Bernard J. Birkett Senior Vice President, Chief Financial Officer February 13, 2025 3 EXHIBIT INDEX Exhibit No. Description 99.1 West Pharmaceutical Services, Inc. Press Release, dated February 13, 2025 . 99.2 West Pharmaceutical Services, Inc. Presentation, dated February 13, 2025 . 104 The cover page from the Company's Current Report on Form 8-K, dated February 13, 2025, formatted in Inline XBRL. 4

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing